NO20076043L - Glucagon-lignende peptid-2 (GLP-2) analoger - Google Patents
Glucagon-lignende peptid-2 (GLP-2) analogerInfo
- Publication number
- NO20076043L NO20076043L NO20076043A NO20076043A NO20076043L NO 20076043 L NO20076043 L NO 20076043L NO 20076043 A NO20076043 A NO 20076043A NO 20076043 A NO20076043 A NO 20076043A NO 20076043 L NO20076043 L NO 20076043L
- Authority
- NO
- Norway
- Prior art keywords
- glp
- analogues
- substitutions
- positions
- disclosed
- Prior art date
Links
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 6
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 2
- 102100040918 Pro-glucagon Human genes 0.000 title 1
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 abstract 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20041—Use of virus, viral particle or viral elements as a vector
- C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C12N2710/22043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
Abstract
GLP-2-analoger er angitt som omfatter en eller flere substitusjoner sammenlignet med [hGly2]GLP-2 og som forbedret biologisk aktivitet in vivo og/eller forbedret kjemisk stabilitet, for eksempel som bestemt i in vitro stabilitetstester. Mer spesielt omfatter foretrukkede GLP-2-analoger angitt her substitusjoner ved en eller flere av posisjoner 8, 16, 24 og/eller 28 av villtype GLP-2-sekvensen, eventuelt i kombinasjon med ytterligere substitusjoner ved posisjon 2 (som nevnt i introduksjonen) og en eller flere av posisjoner 3, 5, 7, 10 og 1 1, og/eller en delesjon av en eller flere av aminosyrer 31 til 33 og/eller tilføyingen av en N-terminal eller C-terminal stabiliserende peptidsekvens. Analogene er spesielt nyttige for profilaksen eller behandlingen av mage- og tarmrelaterte lidelser og for å forbedre bieffekter av kjemoterapi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67806605P | 2005-05-04 | 2005-05-04 | |
| PCT/GB2006/001633 WO2006117565A2 (en) | 2005-05-04 | 2006-05-04 | Glucagon-like-peptide-2 (glp-2) analogues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20076043L true NO20076043L (no) | 2008-02-04 |
| NO345236B1 NO345236B1 (no) | 2020-11-16 |
Family
ID=36649773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20076043A NO345236B1 (no) | 2005-05-04 | 2007-11-23 | Glukagonlignende peptid-2 (GLP-2) analoger, farmasøytiske sammensetninger inneholdende slike og anvendelse for fremstillingen av et medikament for behandlingen og/eller forebyggingen av en mage- og tarmrelatert lidelse, samt nukleinsyremolekyl, ekspresjonsvektor, vertscelle og fremgangsmåter for fremstilling av GLP-2 analogene og et terapeutisk sett. |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US7563770B2 (no) |
| EP (4) | EP1877435B2 (no) |
| JP (3) | JP5405105B2 (no) |
| KR (3) | KR101200227B1 (no) |
| CN (2) | CN101171262B (no) |
| AT (1) | ATE498631T1 (no) |
| AU (1) | AU2006242998B2 (no) |
| BR (1) | BRPI0610091B1 (no) |
| CA (1) | CA2607150C (no) |
| CY (1) | CY1111411T1 (no) |
| DE (1) | DE602006020123D1 (no) |
| DK (1) | DK1877435T4 (no) |
| EA (1) | EA014184B1 (no) |
| ES (1) | ES2361095T5 (no) |
| IL (3) | IL186746A (no) |
| MX (1) | MX2007013431A (no) |
| NO (1) | NO345236B1 (no) |
| NZ (4) | NZ591178A (no) |
| PL (1) | PL1877435T5 (no) |
| PT (1) | PT1877435E (no) |
| SI (1) | SI1877435T2 (no) |
| UA (1) | UA95235C2 (no) |
| WO (1) | WO2006117565A2 (no) |
| ZA (2) | ZA200709384B (no) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| WO2003103475A2 (en) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention and reduction of blood loss |
| JP2005537006A (ja) | 2002-08-28 | 2005-12-08 | ダイアックス、コープ | 臓器及び組織の保存方法 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| DE602006020123D1 (de) * | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| US20070213275A1 (en) * | 2006-03-10 | 2007-09-13 | Dyax Corp. | Formulations for ecallantide |
| JP5373606B2 (ja) * | 2006-07-26 | 2013-12-18 | サンド・アクチエンゲゼルシヤフト | カスポファンギン製剤 |
| WO2008031770A2 (en) * | 2006-09-12 | 2008-03-20 | Cosmo Technologies Ltd | Pharmaceutical compositions for the oral or rectal administration of protein substances |
| AU2007319066B2 (en) | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
| KR20090035279A (ko) * | 2007-10-05 | 2009-04-09 | 경희대학교 산학협력단 | 위장관 손상 예방 및 치료용 조성물 |
| US20090110713A1 (en) * | 2007-10-31 | 2009-04-30 | Florencia Lim | Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices |
| CA2744235A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| CN101824087A (zh) * | 2009-03-05 | 2010-09-08 | 连云港恒邦医药科技有限公司 | 胰高血糖素样肽-2类似物及其制备方法和用途 |
| EP2314616A1 (en) * | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
| EP3459564B1 (en) | 2010-01-06 | 2021-10-27 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| ES2555164T3 (es) | 2010-08-30 | 2015-12-29 | Nps Pharmaceuticals, Inc. | Síntesis de fase sólida de h[Gly2]GLP-2 |
| CA2823776A1 (en) | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| CN102212127B (zh) * | 2011-05-17 | 2015-02-04 | 上海景泽生物技术有限公司 | 胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途 |
| CN102924589B (zh) * | 2011-08-11 | 2016-08-24 | 中肽生化有限公司 | 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途 |
| EP2755675B1 (en) | 2011-09-12 | 2018-06-06 | Amunix Operating Inc. | Glucagon-like peptide-2 compositions and methods of making and using same |
| KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
| CN117462693A (zh) | 2012-02-27 | 2024-01-30 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| AU2013255752B2 (en) | 2012-05-03 | 2017-11-09 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| US20150038674A1 (en) * | 2013-08-05 | 2015-02-05 | Bayrak Bertan Boran | Use of glp-2 analogues in pulmonary diseases for therapeutic purpose |
| IL295414B2 (en) | 2014-03-27 | 2026-02-01 | Takeda Pharmaceuticals Co | Compositions and methods for treating macular edema due to diabetes |
| US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
| US20170087216A1 (en) * | 2015-09-17 | 2017-03-30 | Helsinn Healthcare Sa | Therapeutic Uses of Elsiglutide |
| AU2016366557B2 (en) | 2015-12-11 | 2024-01-25 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| CN107987170B (zh) * | 2016-10-27 | 2018-12-18 | 浙江道尔生物科技有限公司 | 一种用于治疗肠道疾病的融合蛋白 |
| WO2018104558A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| AU2017371516C1 (en) * | 2016-12-09 | 2021-09-02 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
| WO2018104559A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| JP2020500890A (ja) * | 2016-12-09 | 2020-01-16 | ジーランド・ファーマ・ア／エス | Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト |
| WO2018142363A1 (en) * | 2017-02-06 | 2018-08-09 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use compositions of glp-2 analogues through self-administrable devices |
| BR112019026711A2 (pt) | 2017-06-16 | 2020-06-30 | Zealand Pharma A/S | regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2) |
| CA3084326A1 (en) * | 2017-09-28 | 2019-04-04 | Jaehyuk Choi | Long-acting conjugates of glp-2 derivatives |
| WO2019086559A1 (fr) | 2017-10-31 | 2019-05-09 | Adocia | Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
| WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
| EP3628682A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| EP3628683A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| EP3924369A1 (en) * | 2019-02-11 | 2021-12-22 | OPKO Biologics Ltd. | Long-acting glp-2 analogs |
| BR112021020941A2 (pt) | 2019-06-14 | 2021-12-21 | Zealand Pharma As | Composição farmacêutica parenteral isotônica, método para melhoria da estabilidade química da dita composição e uso de manitol |
| CN110305223B (zh) | 2019-06-26 | 2022-05-13 | 重庆派金生物科技有限公司 | 重组串联融合蛋白制备目标多肽的方法 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| AU2020397917A1 (en) | 2019-12-04 | 2022-06-23 | The Scripps Research Institute | GLP2 receptor agonists and methods of use |
| US12528880B2 (en) | 2020-01-13 | 2026-01-20 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| EP4126004A1 (en) | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Agonist combination |
| EP4144361A4 (en) * | 2020-04-03 | 2024-05-22 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY OR A COMBINATION THEREOF, WITH GLP-2 DERIVATIVES OR LONG-ACTING CONJUGATE THEREOF |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN111560061A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Gelpaglutide的制备方法 |
| CN111560062A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Elisiglutide的制备方法 |
| KR20230038187A (ko) | 2020-06-09 | 2023-03-17 | 벡티브바이오 에이지 | 아프라글루타이드의 제조, 제형화 및 투여 |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| MX2023006901A (es) | 2020-12-16 | 2023-06-26 | Zealand Pharma As | Uso de analogos de glp-2 en pacientes con insuficiencia renal. |
| TW202241491A (zh) * | 2020-12-16 | 2022-11-01 | 丹麥商西蘭製藥公司 | Ｇｌｐ－１／ｇｌｐ－２雙重促效劑之醫藥組合物 |
| MX2023014771A (es) | 2021-06-09 | 2024-03-19 | Scripps Research Inst | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. |
| CN115636876A (zh) * | 2021-07-20 | 2023-01-24 | 重庆派金生物科技有限公司 | 胰高血糖素样肽-2突变体的定向化学偶联物及其应用 |
| AU2022341538A1 (en) | 2021-09-10 | 2024-04-11 | Zealand Pharma A/S | Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues |
| WO2023118416A1 (en) | 2021-12-23 | 2023-06-29 | Zealand Pharma A/S | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
| EP4572783A1 (en) | 2022-09-30 | 2025-06-25 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
| IL322328A (en) | 2023-01-27 | 2025-09-01 | Zealand Pharma As | Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS) |
| CN116478269A (zh) * | 2023-04-28 | 2023-07-25 | 成都奥达生物科技有限公司 | 一种长效替度鲁肽化合物 |
| CN116751278B (zh) * | 2023-06-21 | 2024-02-13 | 杭州信海医药科技有限公司 | 一种Glepaglutide的制备方法 |
| WO2025141129A1 (en) | 2023-12-28 | 2025-07-03 | Zealand Pharma A/S | Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses |
| WO2025162422A1 (zh) * | 2024-01-31 | 2025-08-07 | 杭州先为达生物科技股份有限公司 | 胰高血糖素样肽2衍生物及其应用 |
| WO2025181330A1 (en) | 2024-02-29 | 2025-09-04 | Vectivbio Ag | Dosage regimens for glucagon-like peptide 2 (glp-2) analogs |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| JP2961045B2 (ja) * | 1993-02-24 | 1999-10-12 | 日清製粉株式会社 | 腸管粘膜増強促進剤 |
| US6184208B1 (en) | 1994-06-29 | 2001-02-06 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| DE69717092T2 (de) † | 1996-03-01 | 2003-07-24 | Novo Nordisk A/S, Bagsvaerd | Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid |
| US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| DE60142885D1 (de) * | 1996-04-12 | 2010-10-07 | Ontario Inc 1149336 | Dem Glukagon ähnliches Peptid-2 |
| US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
| US20020025933A1 (en) | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| US5952301A (en) * | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| US6051557A (en) | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
| DK0981362T3 (da) † | 1997-05-16 | 2004-03-15 | Ontario Inc 1149336 | Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal |
| AU766219B2 (en) * | 1998-02-02 | 2003-10-09 | 1149336 Ontario Inc. | Method of regulating glucose metabolism, and reagents related thereto |
| JP4394279B2 (ja) | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体 |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2001041779A2 (en) | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| ES2310192T3 (es) | 2000-09-18 | 2009-01-01 | Sanos Bioscience A/S | Uso de peptidos glp-2. |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| WO2002066062A2 (en) | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
| ATE396202T1 (de) | 2001-02-16 | 2008-06-15 | Conjuchem Biotechnologies Inc | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen |
| US7144863B2 (en) * | 2001-06-01 | 2006-12-05 | Eli Lilly And Company | GLP-1 formulations with protracted time action |
| WO2004035624A2 (en) * | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
| WO2004085471A2 (en) * | 2003-03-24 | 2004-10-07 | Novo Nordisk A/S | Glp-2 derivatives |
| KR101241862B1 (ko) * | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| ES2427150T3 (es) * | 2004-11-01 | 2013-10-29 | Nps Pharmaceuticals, Inc. | Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad |
| DE602006020123D1 (de) | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| AU2007319066B2 (en) * | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| US8685919B2 (en) | 2008-12-15 | 2014-04-01 | Zealand Pharma A/S | Glucagon analogues |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| KR20240110072A (ko) | 2011-05-18 | 2024-07-12 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
-
2006
- 2006-05-04 DE DE602006020123T patent/DE602006020123D1/de active Active
- 2006-05-04 MX MX2007013431A patent/MX2007013431A/es active IP Right Grant
- 2006-05-04 BR BRPI0610091-0A patent/BRPI0610091B1/pt active IP Right Grant
- 2006-05-04 DK DK06727006.6T patent/DK1877435T4/da active
- 2006-05-04 PL PL06727006T patent/PL1877435T5/pl unknown
- 2006-05-04 KR KR1020077028167A patent/KR101200227B1/ko active Active
- 2006-05-04 CN CN2006800152135A patent/CN101171262B/zh active Active
- 2006-05-04 CN CN201210124331.7A patent/CN102659938B/zh not_active Expired - Fee Related
- 2006-05-04 AU AU2006242998A patent/AU2006242998B2/en active Active
- 2006-05-04 PT PT06727006T patent/PT1877435E/pt unknown
- 2006-05-04 EP EP06727006.6A patent/EP1877435B2/en active Active
- 2006-05-04 EP EP10009232A patent/EP2295452A1/en not_active Withdrawn
- 2006-05-04 KR KR1020117015196A patent/KR101242795B1/ko not_active Expired - Fee Related
- 2006-05-04 ES ES06727006T patent/ES2361095T5/es active Active
- 2006-05-04 CA CA2607150A patent/CA2607150C/en active Active
- 2006-05-04 WO PCT/GB2006/001633 patent/WO2006117565A2/en not_active Ceased
- 2006-05-04 NZ NZ591178A patent/NZ591178A/en not_active IP Right Cessation
- 2006-05-04 NZ NZ562943A patent/NZ562943A/en not_active IP Right Cessation
- 2006-05-04 UA UAA200713558A patent/UA95235C2/ru unknown
- 2006-05-04 EP EP10009231A patent/EP2295451A1/en not_active Withdrawn
- 2006-05-04 EP EP18206332.1A patent/EP3473646A1/en active Pending
- 2006-05-04 NZ NZ591179A patent/NZ591179A/en not_active IP Right Cessation
- 2006-05-04 EA EA200702408A patent/EA014184B1/ru unknown
- 2006-05-04 SI SI200630985T patent/SI1877435T2/sl unknown
- 2006-05-04 KR KR1020117015195A patent/KR101242951B1/ko not_active Expired - Fee Related
- 2006-05-04 JP JP2008509505A patent/JP5405105B2/ja active Active
- 2006-05-04 NZ NZ593050A patent/NZ593050A/xx unknown
- 2006-05-04 AT AT06727006T patent/ATE498631T1/de active
- 2006-05-04 US US11/429,168 patent/US7563770B2/en active Active
- 2006-11-09 US US11/595,496 patent/US7745403B2/en active Active
-
2007
- 2007-10-18 IL IL186746A patent/IL186746A/en active IP Right Grant
- 2007-10-31 ZA ZA2007/09384A patent/ZA200709384B/en unknown
- 2007-11-23 NO NO20076043A patent/NO345236B1/no unknown
-
2009
- 2009-12-21 US US12/643,233 patent/US8263552B2/en active Active
- 2009-12-21 US US12/643,261 patent/US8163696B2/en active Active
-
2011
- 2011-01-16 IL IL210669A patent/IL210669A/en active IP Right Grant
- 2011-01-16 IL IL210668A patent/IL210668A/en active IP Right Grant
- 2011-01-28 ZA ZA2011/00753A patent/ZA201100753B/en unknown
- 2011-05-05 CY CY20111100436T patent/CY1111411T1/el unknown
-
2012
- 2012-06-28 US US13/536,377 patent/US9125882B2/en active Active
-
2013
- 2013-04-03 JP JP2013077830A patent/JP5876434B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-08 US US14/847,938 patent/US9580487B2/en active Active
- 2015-10-01 JP JP2015196105A patent/JP6272284B2/ja active Active
-
2017
- 2017-01-20 US US15/411,649 patent/US20170137487A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1877435T4 (da) | Glucagon-lignende-peptid-2 (glp-2)-analoger | |
| UA102506C2 (ru) | Селективные аналоги глюкагоноподобного пептида-2 (glp-2) | |
| BRPI0811320A2 (pt) | Surfactantes reconstituídos com propriedades melhoradas | |
| PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| PE20090711A1 (es) | Region constante de anticuerpo mutante | |
| PE20120021A1 (es) | Mutantes fgf21 | |
| ATE417595T1 (de) | Keratin-bindende polypeptide | |
| AR094178A1 (es) | Derivados de exendina-4 funcionalizada | |
| PE20130615A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
| JP2013500990A5 (no) | ||
| SG178797A1 (en) | Oligosaccharide chain added glp-1 peptide | |
| AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
| NZ593190A (en) | Factor viii formulations | |
| NO20081654L (no) | Stabiliserte GLP-1-analoger | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| ATE548380T1 (de) | Mutante des hgf-precursor-proteins und aktivierte form davon | |
| DE60118418D1 (de) | Maurotoxin, pi1 und hstx1 derivate | |
| DE602007009797D1 (de) | Antitumorheilmittel, Medikament, Zusammensetzung und Verwendung davon |